[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"baotai Liang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":120},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,60,80,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100612204","phase-2-a-clinical-study-on-the-efficacy-and-safety-of-fasudil-hydrochloride-combined-with-immunotherapy-in-the-treatment-of-metastatic-castration-resistant-prostate-cancer-100612204",false,"NCT07250542","A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 years and \\\u003C 85 years;\n2. Patients who have failed at least one chemotherapy regimen containing docetaxel and one standard novel endocrine therapy;\n3. Diagnosed with CRPC, defined as: after continuous castration therapy, the castration level of testosterone is \\\u003C 50 ng\u002Fml; disease progression within 12 weeks before enrollment: PSA levels increase consecutively for 3 times at intervals of 1 week, and serum PSA ≥ 2 ng\u002Fml; evaluated as soft tissue progression according to RECIST criteria, or ≥ 2 new lesions on bone scan;\n4. Imaging evidence indicates bone metastatic disease and\u002For measurable non-bone metastatic disease (lymph nodes or internal organs); Expected survival period ≥ 3 months; All patients voluntarily signed the informed consent form and were able to cooperate with treatment and follow-up;\n\nExclusion Criteria:\n\n1. Severe cardiovascular and cerebrovascular diseases;\n2. Abnormal liver function: Total bilirubin in blood is less than 1.5 times the upper limit of normal value, and the ratio of blood ALT to AST is less than 2 times the upper limit of normal value;\n3. Abnormal kidney function: Serum creatinine is less than 1.5 mg\u002Fdl or the creatinine clearance rate is greater than or equal to 60 cc\u002Fmin;\n4. Those allergic to the used drugs;\n5. Those with tumors in other parts;\n6. Abnormal thyroid function: Blood FT4 and\u002For TT4 levels are higher or lower than the normal value (normal blood FT4 level is 9-25 pmol\u002FL (0.7-1.9 ng\u002Fdl), normal blood TT4 level is 64-154 nmol\u002FL (5-12 ug\u002Fdl));\n7. Cortisol deficiency: Serum cortisol at 8 a.m. is less than 140 nmol\u002FL (5 ug\u002FdL).","MALE","18 Years","85 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Carrying out clinical trials of salbutamol hydrochloride combined with immunotherapy and castration for the treatment of prostate cancer is of great significance. Firstly, it can verify the efficacy and safety of this combination in the treatment of prostate cancer, providing a scientific basis for its clinical application. Secondly, through clinical trials, the mechanism of action of salbutamol hydrochloride combined with immunotherapy can be further studied. Finally, this clinical trial can further expand the treatment strategies for prostate cancer.",[26],"Prostate Cancer","RECRUITING","2025-11-25",{"date":30,"type":31},"2025-11-26","ACTUAL",{"date":33,"type":31},"2024-07-05",{"date":35,"type":20},"2026-12-30",{"name":37,"class":38},"baotai Liang","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":39},"100605545","phase-2-homoharringtonine-plus-androgen-deprivation-therapy-in-the-neoadjuvant-treatment-of-prostate-cancer-a-single-arm-clinical-study-100605545","NCT07163910","Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study","Clinical Study of Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of Prostate Cancer","Inclusion Criteria：\n\n① Aged ≥ 18 years and ≤ 85 years;\n\n* Histologically or cytologically confirmed prostate cancer;\n\n  * Patients meeting any of the following disease staging criteria:\n\n    1. Localized high-risk\u002Fvery high-risk prostate cancer: meeting at least one of the following characteristics (clinical stage T3-T4, Gleason score ≥ 8, primary Gleason pattern 5, or PSA \\> 20 ng\u002FmL), with no local lymph node metastasis (N0) and no distant metastasis (M0);\n    2. Prostate cancer with local lymph node metastasis: presence of local lymph node metastasis (N1) but no distant metastasis (M0);\n    3. Metastatic prostate cancer: confirmed as metastatic prostate cancer by imaging examinations; ④ Physical status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1; ⑤ Informed consent: All patients voluntarily sign the informed consent form and can adhere to treatment and follow-up.\n\n       Exclusion Criteria：\n\n       ① Any previous or ongoing prostate cancer treatment, including radiotherapy, chemotherapy, androgen deprivation therapy (ADT), etc.;\n* A history of previous prostatectomy;\n\n  * Any other severe underlying medical, psychiatric, or psychological diseases that, in the investigator's judgment, may affect the treatment;\n\n    * A history of allergy to the drugs used in the study; ⑤ Refusal to undergo radical prostatectomy; ⑥ Ineligibility to participate in this clinical trial as judged by the investigator.",{"count":48,"type":20},93,[23],"The project aims to verify the therapeutic effect of neoadjuvant homoharringtonine combined with androgen deprivation therapy in patients with localized high-risk\u002Fvery high-risk, regional lymph node-metastatic, or metastatic prostate cancer before radical prostatectomy through clinical trials, thereby identifying an effective treatment for patients with advanced prostate cancer.",[26],"2025-11-17",{"date":54,"type":31},"2025-11-18",{"date":56,"type":31},"2025-04-20",{"date":58,"type":20},"2027-12-20",{"name":37,"class":38},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":39},"100582275","phase-2-clinical-study-of-fasudil-hydrochloride-and-pd1-inhibitor-combined-with-androgen-deprivation-in-neoadjuvant-therapy-of-prostate-cancer-100582275","NCT06861192","Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer","A Randomized Controlled Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy for Prostate Cancer","Inclusion Criteria:\n\n* ① Age ≥18 years and ≤85 years;\n\n  * Histologically confirmed prostate cancer without small cell features;\n\n    * Metastatic prostate cancer was identified by imaging examination with ≤5 oligometastases (bone or lymph node metastases) or cT3-4 stages; ④The score of ECOG (Eastern Cooperative Oncology Group) was 0-1; ⑤ All patients voluntarily sign informed consent, and can adhere to treatment and follow-up;\n\nExclusion Criteria:\n\n* ①Any previous or ongoing PCa treatment, including radiotherapy, chemotherapy, ADT, etc.\n\n  * Previous prostatectomy;\n\n    * Any other serious basic medical, mental, psychological, and other diseases that, in the judgment of the investigator, may affect the treatment of the patient\n\n      * Allergic to the drugs used; ⑤ Refuse to undergo radical prostatectomy; ⑥ According to the investigator's judgment, it is not suitable to participate in this clinical trial;",{"count":68,"type":20},83,[23,70],"PHASE3","The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although neoadjuvant androgen deprivation therapy combined with radical prostatectomy reduced the positive rate of surgical margins, it did not show statistically significant improvement in prostate-specific antigen (PSA). At the same time, few trials reported pathological complete response (pCR) and minimal residual lesion (MRD).\n\nThe purpose of this project is to verify the therapeutic effect of fasudil hydrochloride and PD1 inhibitor combined with androgen deprivation in patients with locally advanced prostate cancer or oligometastatic prostate cancer before radical prostatectomy through randomized controlled clinical trials, so as to find an effective treatment for locally advanced prostate cancer or oligometastatic prostate cancer.",[73],"Prostate CA",{"date":54,"type":31},{"date":76,"type":31},"2025-02-16",{"date":78,"type":20},"2027-03-16",{"name":37,"class":38},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100580209","phase-2-clinical-study-on-neoadjuvant-therapy-of-homoharringtonine-combined-with-androgen-deprivation-for-prostate-cancer-100580209","NCT06834321","Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer","A Randomized Controlled Study of Homoharringtonine Combined With Androgen Deprivation in Neoadjuvant Therapy for Prostate Cancer",{"count":87,"type":20},96,[23],"The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although neoadjuvant androgen deprivation therapy combined with radical prostatectomy reduced the positive rate of surgical margins, it did not show statistically significant improvement in prostate-specific antigen (PSA). At the same time, few trials reported pathological complete response (pCR) and minimal residual lesion (MRD).\n\nThe purpose of this project is to verify the therapeutic effect of homoharringtonine combined androgen deprivation in patients with locally advanced prostate cancer or oligometastatic prostate cancer before radical prostatectomy through a randomized controlled clinical trial, so as to find an effective treatment for locally advanced prostate cancer or oligometastatic prostate cancer.",[73],"2025-08-31",{"date":93,"type":31},"2025-09-08",{"date":95,"type":31},"2025-03-19",{"date":97,"type":20},"2027-09-28",{"name":37,"class":38},2,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":4},"100582273","phase-2-clinical-study-of-geranium-wilfordii-combined-with-androgen-deprivation-in-neoadjuvant-therapy-of-prostate-cancer-100582273","NCT06861166","Clinical Study of Geranium Wilfordii Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer","Randomized Controlled Study of Geranium Wilfordii Combined With Androgen Deprivation in Neoadjuvant Therapy for Prostate Cancer",{"count":107,"type":20},95,[23,70],"The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although neoadjuvant androgen deprivation therapy combined with radical prostatectomy reduced the positive rate of surgical margins, it did not show statistically significant improvement in prostate-specific antigen (PSA). At the same time, few trials reported pathological complete response (pCR) and minimal residual lesion (MRD).\n\nThe purpose of this project is to verify the efficacy of geranium combined with androgen deprivation in the treatment of locally advanced prostate cancer or oligometastatic prostate cancer before radical prostatectomy through randomized controlled clinical trials, so as to find an effective treatment for locally advanced prostate cancer or oligometastatic prostate cancer.",[73],"NOT_YET_RECRUITING","2025-03-05",{"date":114,"type":31},"2025-03-06",{"date":116,"type":20},"2025-03-10",{"date":118,"type":20},"2027-03-10",{"name":37,"class":38},""]